Literature DB >> 25712460

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

C H Chung1, V B Guthrie2, D L Masica2, C Tokheim2, H Kang3, J Richmon4, N Agrawal4, C Fakhry5, H Quon6, R M Subramaniam7, Z Zuo8, T Seiwert8, Z R Chalmers9, G M Frampton9, S M Ali9, R Yelensky9, P J Stephens9, V A Miller9, R Karchin10, J A Bishop11.   

Abstract

BACKGROUND: To determine genomic alterations in head and neck squamous cell carcinoma (HNSCC) using formalin-fixed, paraffin-embedded (FFPE) tumors obtained through routine clinical practice, selected cancer-related genes were evaluated and compared with alterations seen in frozen tumors obtained through research studies. PATIENTS AND METHODS: DNA samples obtained from 252 FFPE HNSCC were analyzed using next-generation sequencing-based (NGS) clinical assay to determine sequence and copy number variations in 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer. Human papillomavirus (HPV) status was determined by presence of the HPV DNA sequence in all samples and corroborated with high-risk HPV in situ hybridization (ISH) and p16 immunohistochemical (IHC) staining in a subset of tumors. Sequencing data from 399 frozen tumors in The Cancer Genome Atlas and University of Chicago public datasets were analyzed for comparison.
RESULTS: Among 252 FFPE HNSCC, 84 (33%) were HPV positive and 168 (67%) were HPV negative by sequencing. A subset of 40 tumors with HPV ISH and p16 IHC results showed complete concordance with NGS-derived HPV status. The most common genes with genomic alterations were PIK3CA and PTEN in HPV-positive tumors and TP53 and CDKN2A/B in HPV-negative tumors. In the pathway analysis, the PI3K pathway in HPV-positive tumors and DNA repair-p53 and cell cycle pathways in HPV-negative tumors were frequently altered. The HPV-positive oropharynx and HPV-positive nasal cavity/paranasal sinus carcinoma shared similar mutational profiles.
CONCLUSION: The genomic profile of FFPE HNSCC tumors obtained through routine clinical practice is comparable with frozen tumors studied in research setting, demonstrating the feasibility of comprehensive genomic profiling in a clinical setting. However, the clinical significance of these genomic alterations requires further investigation through application of these genomic profiles as integral biomarkers in clinical trials.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  DNA mutation; copy number variation; head and neck squamous cell carcinoma; human papillomavirus

Mesh:

Substances:

Year:  2015        PMID: 25712460      PMCID: PMC4516044          DOI: 10.1093/annonc/mdv109

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  27 in total

1.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

2.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

3.  Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

Authors:  Nishant Agrawal; Mitchell J Frederick; Curtis R Pickering; Chetan Bettegowda; Kyle Chang; Ryan J Li; Carole Fakhry; Tong-Xin Xie; Jiexin Zhang; Jing Wang; Nianxiang Zhang; Adel K El-Naggar; Samar A Jasser; John N Weinstein; Lisa Treviño; Jennifer A Drummond; Donna M Muzny; Yuanqing Wu; Laura D Wood; Ralph H Hruban; William H Westra; Wayne M Koch; Joseph A Califano; Richard A Gibbs; David Sidransky; Bert Vogelstein; Victor E Velculescu; Nickolas Papadopoulos; David A Wheeler; Kenneth W Kinzler; Jeffrey N Myers
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

4.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Authors:  Robert J Motzer; Camillo Porta; Nicholas J Vogelzang; Cora N Sternberg; Cezary Szczylik; Jakub Zolnierek; Christian Kollmannsberger; Sun Young Rha; Georg A Bjarnason; Bohuslav Melichar; Ugo De Giorgi; Viktor Grünwald; Ian D Davis; Jae-Lyun Lee; Emilio Esteban; Gladys Urbanowitz; Can Cai; Matthew Squires; Mahtab Marker; Michael M Shi; Bernard Escudier
Journal:  Lancet Oncol       Date:  2014-02-17       Impact factor: 41.316

Review 5.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

6.  Tobacco and alcohol and the risk of head and neck cancer.

Authors:  H Maier; A Dietz; U Gewelke; W D Heller; H Weidauer
Journal:  Clin Investig       Date:  1992 Mar-Apr

7.  Case-control study of human papillomavirus and oropharyngeal cancer.

Authors:  Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

8.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

9.  Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.

Authors:  Teresa Davoli; Andrew Wei Xu; Kristen E Mengwasser; Laura M Sack; John C Yoon; Peter J Park; Stephen J Elledge
Journal:  Cell       Date:  2013-10-31       Impact factor: 41.582

10.  PID: the Pathway Interaction Database.

Authors:  Carl F Schaefer; Kira Anthony; Shiva Krupa; Jeffrey Buchoff; Matthew Day; Timo Hannay; Kenneth H Buetow
Journal:  Nucleic Acids Res       Date:  2008-10-02       Impact factor: 16.971

View more
  59 in total

1.  Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.

Authors:  Haixia Cheng; Elana J Fertig; Hiroyuki Ozawa; Hiromitsu Hatakeyama; Jason D Howard; Jimena Perez; Michael Considine; Manjusha Thakar; Ruchira Ranaweera; Gabriel Krigsfeld; Christine H Chung
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

2.  Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors.

Authors:  Ayse Selen Yilmaz; Hatice Gulcin Ozer; Jessica L Gillespie; Dawn C Allain; Madison N Bernhardt; Karina Colossi Furlan; Leticia T F Castro; Sara B Peters; Priyadharsini Nagarajan; Stephen Y Kang; O Hans Iwenofu; Thomas Olencki; Theodoros N Teknos; Amanda Ewart Toland
Journal:  Cancer       Date:  2016-12-01       Impact factor: 6.860

Review 3.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.

Authors:  Lester D R Thompson; Alessandro Franchi
Journal:  Virchows Arch       Date:  2017-04-25       Impact factor: 4.064

4.  PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Authors:  Nnamdi Eze; Ju-Whei Lee; Dong-Hua Yang; Fang Zhu; Veronique Neumeister; Teresa Sandoval-Schaefer; Ranee Mehra; John A Ridge; Arlene Forastiere; Christine H Chung; Barbara Burtness
Journal:  Oral Oncol       Date:  2019-03-04       Impact factor: 5.337

Review 5.  The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.

Authors:  Keiichi Koshizuka; Toyoyuki Hanazawa; Ichiro Fukumoto; Naoko Kikkawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-08-25       Impact factor: 3.172

Review 6.  The molecular landscape of head and neck cancer.

Authors:  C René Leemans; Peter J F Snijders; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

7.  The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma.

Authors:  Alexandre A B A da Costa; Felipe D'Almeida Costa; Daniel Vilarim Araújo; Marcos Pedro Guedes Camandaroba; Victor Hugo Fonseca de Jesus; Audrey Oliveira; Ana Caroline Fonseca Alves; Carlos Stecca; Larissa Machado; Andrea Cruz Feraz de Oliveira; Thiago Bueno de Oliveira; Ulisses Ribaldo Nicolau; Vladmir Cláudio Cordeiro de Lima
Journal:  Med Oncol       Date:  2018-11-26       Impact factor: 3.064

Review 8.  Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.

Authors:  D Neil Hayes; Carter Van Waes; Tanguy Y Seiwert
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 9.  The potential for liquid biopsies in head and neck cancer.

Authors:  Matthew E Spector; Janice L Farlow; Catherine T Haring; J Chad Brenner; Andrew C Birkeland
Journal:  Discov Med       Date:  2018-05       Impact factor: 2.970

10.  Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC).

Authors:  Ritu Chaudhary; Xuefeng Wang; Biwei Cao; Janis De La Iglesia; Jude Masannat; Feifei Song; Juan C Hernandez-Prera; Nicholas T Gimbrone; Robbert Jc Slebos; Christine H Chung
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.